» Articles » PMID: 28220805

Meta-analysis of Metabolic Syndrome and Prostate Cancer

Overview
Specialties Oncology
Urology
Date 2017 Feb 22
PMID 28220805
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Metabolic syndrome (MetS) and prostate cancer (PCa) are highly prevalent conditions worldwide. Current evidence suggests the emerging hypothesis that MetS could play a role in the development and progression of several neoplasms. The aims of this study are to evaluate the impact of MetS and MetS factors on PCa incidence, on the risk of high-grade PCa and to analyze the role of MetS and single MetS components on the development of aggressive PCa features.

Methods: A systematic literature search and analysis on PubMed, EMBASE, Cochrane and Academic One File databases until September 2015 was performed by 2 independent reviewers to evaluate the associations between MetS and PCa incidence, and between MetS and high-grade PCa incidence (bioptical Gleason Score⩾8, Prognostic Group 4-5 according to the novel prostate cancer grading system). Also the association between MetS and individual MetS components with pathological Gleason Score⩾8, extra-capsular extension, seminal vesicle invasion, positive surgical margins and biochemical recurrence (defined as two consecutive PSA values ⩾0.2 ng ml after radical prostatectomy) was evaluated.

Results: 24 studies were selected including a total of 132 589 participants of whom 17.35% had MetS. There was a slight association between MetS and PCa incidence (odds ratio (OR)=1.17 (1.00-1.36), P=0.04) and between high-grade PCa and MetS (OR= 1.89 (1.50-2.38), P<0.0001) but the studies were statistically heterogeneous. No association was found between MetS components and PCa risk except for hypertension. MetS was significantly associated with pathologic Gleason Score⩾8 (OR= 1.77 (1.34-2.34); P<0.01), extra-capsular extension (OR=1.13 (1.09-1.18); P<0.01), seminal vesicle invasion (OR=1.09 (1.07-1.12); P<0.01), positive surgical margins (OR=1.67 (1.47-1.91); P<0.01) and biochemical recurrence (OR=1.67 (1.04-2.69); P<0.01).

Conclusions: The presence of MetS is associated with worse oncologic outcomes in men with PCa, in particular with more aggressive tumor features, and biochemical recurrence.

Citing Articles

Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study.

Lee S, Niksic M, Luque-Fernandez M Sci Rep. 2025; 15(1):2345.

PMID: 39824873 PMC: 11748637. DOI: 10.1038/s41598-025-85501-5.


Machine learning algorithms that predict the risk of prostate cancer based on metabolic syndrome and sociodemographic characteristics: a prospective cohort study.

Tran T, Lee J, Kim J, Kim S, Cho H, Kim J BMC Public Health. 2024; 24(1):3549.

PMID: 39707344 PMC: 11662620. DOI: 10.1186/s12889-024-20852-8.


Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer.

Beitzen-Heineke A, Wise D, Berger J Cardiooncology. 2024; 10(1):87.

PMID: 39639392 PMC: 11619638. DOI: 10.1186/s40959-024-00278-2.


Systemic immune-inflammation index is associated with high risk for prostate cancer among the U.S. elderly: Evidence from NHANES 2001-2010.

He R, Ye Y, Zhu Q, Xie C Front Oncol. 2024; 14:1441271.

PMID: 39376981 PMC: 11456397. DOI: 10.3389/fonc.2024.1441271.


Association between metabolic obesity phenotypes and the risk of developing prostate cancer: a propensity score matching study based on Xinjiang.

Wang J, Apizi A, Qiu H, Tao N, An H Front Endocrinol (Lausanne). 2024; 15:1442740.

PMID: 39165513 PMC: 11333236. DOI: 10.3389/fendo.2024.1442740.


References
1.
Martin R, Vatten L, Gunnell D, Romundstad P, Nilsen T . Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control. 2009; 20(7):1181-92. DOI: 10.1007/s10552-009-9319-x. View

2.
Chan J, Latini D, Cowan J, DuChane J, Carroll P . History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control. 2005; 16(7):789-97. DOI: 10.1007/s10552-005-3301-z. View

3.
Hsing A, Sakoda L, Chua Jr S . Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2008; 86(3):s843-57. DOI: 10.1093/ajcn/86.3.843S. View

4.
Beebe-Dimmer J, Dunn R, Sarma A, Montie J, Cooney K . Features of the metabolic syndrome and prostate cancer in African-American men. Cancer. 2007; 109(5):875-81. DOI: 10.1002/cncr.22461. View

5.
Zhang P, Rosen S, Veeramachaneni R, Kao J, DeWolf W, Bubley G . Association between prostate cancer and serum testosterone levels. Prostate. 2002; 53(3):179-82. DOI: 10.1002/pros.10140. View